| Issue Date | Title | Author(s) |
| 1 | 2021 | Advantage of co-culture strategy for targeted cancer treatment and in vitro studies | Ulu, Gizem Tuğçe ; Bayram, Nazende Nur; Dinçer İşoğlu, Sevil; Baran, Yusuf |
| 2 | 2014 | Cytotoxic and apoptotic effects of fisetin, hesperetin and vitexinon acute promyelocytic leukemia cells | Adan Gökbulut, Aysun ; Baran, Yusuf |
| 3 | 2014 | Effects of hesperidin on non-small cell lung cancer cells | Bireller, Elif Sinem; Cincin, Zeynep Birsu; Ünlü, Miray ; Kıran, Bayram; Baran, Yusuf ; Çakmakoğlu, Bedia |
| 4 | 2014 | A novel biomarker for drug resistance in chronic myeloid leukemia: MicroRNA-17 | Baran, Yusuf ; Fıratlıgil, Burcu ; Kartal Yandım, Melis; Kiraz, Yağmur ; Kozanoğlu, İlknur; Özdoğu, Hakan; Ünal, Ali |
| 5 | Apr-2022 | Peptıde targeted core cross-lınked mıcelles for dox delıvery to HER2 expressıng cancer cells | Bayram, Nazende Nur; Ulu, Gizem Tuğçe ; Gürdap, Seda; İşoğlu, İsmail Alper; Baran, Yusuf ; Dinçer İşoğlu, Sevil |
| 6 | 2007 | A study of multiple drug resistance mechanisms improved against Bortezomib on multiple myeloma cell lines in vitro | Uyuklu, Tolga; Ural, A. Uğur; Sarper, Metal; Avcu, Ferit; Baran, Yusuf ; Elçi, Pınar; Akar, Nejat |
| 7 | 2014 | Targeting sphingosine kinase-1/spingosine-1-phosphate receptor 2 signalling pathway to overcome T315I mutation in 32DCL3 cells | Adan Gökbulut, Aysun ; Öğretmen, Besim; Baran, Yusuf |
| 8 | 2014 | Therapeutic potential of fisetin, vitexin and hesperetin on chronic myeloid leukemia cells | Adan Gökbulut, Aysun ; Baran, Yusuf |
